## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application.

(Currently Amended) A process for preparing the intermediate
 (2-(2,3-dichlorophenyl)-2-(aminoguanidine)acetonitrile, of formula
 (II):

$$H_2N$$
 $N \longrightarrow N$ 
 $N \longrightarrow N$ 
 $N \longrightarrow N$ 

(II)

which comprises the reaction of 2,3-dichlorobenzoyl cyanide with aminoguanidine bicarbonate, characterised in that wherein it is carried out in non-aqueous medium in the presence of methanesulphonic acid as the only reaction medium.

- 2. (Currently Amended) Process according to Claim 1, characterised in that wherein said reaction is carried out within a temperature range of 20 to 80°C.
- 3. (Currently Amended) Process according to Claim 2, characterised in that wherein said reaction is carried out within a temperature range of 30 to 60°C.

- 4. (Currently Amended) Process according to Claim 1, characterised in that wherein, once the reaction has finished, it comprises an additional step that consists in:
  - (i) addition of water; and
- (ii) adjustment of the pH of the medium until a pH higher than the pKa of the hydrogen cyanide is achieved.
- 5. (Currently Amended) Process according to Claim 4, characterised in that wherein in ii), said adjustment of the pH is carried out by adding a sodium hydroxide solution.
- 6. (Currently Amended) Process for preparing the 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine, of formula (I):

$$N \longrightarrow N$$
 $N \longrightarrow N$ 
 $N \longrightarrow N$ 
 $N \longrightarrow N$ 
 $N \longrightarrow N$ 
 $N \longrightarrow N$ 

(I)

or a pharmaceutically acceptable salt thereof, which comprises the following steps:

- a) preparation of the intermediate 2-(2,3-dichlorophenyl)-2-(aminoguanidine)acetonitrile, of formula (II), according to any of claims 1 to 5 claim 1;
- b) cyclisation of said intermediate of formula (II) in an aliphatic alcohol or in an aliphatic alcohol/water solution under reflux; and, if desired, obtaining a pharmaceutically acceptable salt thereof.

7. (Currently Amended) Process according to Claim 6, characterised in that wherein said aliphatic alcohol used in step b) may be chosen from between ethanol and isopropanol.